Nuclear Medicine: Page 372

Cytogen revenues up in Q1, but loss widens

By AuntMinnie.com staff writers

Biopharmaceutical firm Cytogen reported first-quarter total product revenues of $4 million, up 10% compared with the $3.6 million posted last year.

May 4, 2005

BrachySil data to debut at ESTRO

By AuntMinnie.com staff writers

Biomedical nanotechnology firm pSivida of Perth, Australia, said that current data from its BrachySil cancer therapy product investigational trials will be presented at the European Society for Therapeutic and Radiation Oncology (ESTRO) conference in Budapest, Hungary, this week.

May 3, 2005

Digirad revenues rise, but loss widens in Q1

By AuntMinnie.com staff writers

Nuclear medicine vendor Digirad reported first-quarter revenues of $18 million, up 13% compared with the $15.9 million turned in during the first quarter of 2004.

May 2, 2005

Gamma-based imaging proves useful in breast cancer metastases

By Shalmali Pal

Two recent studies have taken a closer look at the role of gamma cameras and gamma probes in tracking the spread of breast cancer. In the first study, Japanese researchers compared SPECT to FDG-PET for detecting bone metastasis to the axial skeleton in breast cancer cases. In the second paper, French authors compared gamma probes for sentinel lymph node detection, which is an important guide for therapeutic choices.

April 28, 2005

Immunomedics to raise $36 million

By AuntMinnie.com staff writers

Radiopharmaceutical firm Immunomedics said it has signed definitive agreements to complete approximately $36 million in financing through the issuance of senior convertible notes and common stock warrants.

April 27, 2005

Draxis names president of radiopharmaceuticals group

Draxis Health of Mississauga, Ontario, has selected Jean-Pierre Robert as the new president of its radiopharmaceuticals division in Montreal.

April 26, 2005

More PET/CT lung masses seen with hardware-based fusion

By Eric Barnes

Two new studies underscore the superiority of PET/CT for imaging lung lesions compared to either modality alone. The first found that different fusion methods produce substantially different results, while the second found that PET/CT has higher sensitivity, specificity, and positive and negative predictive values than either modality alone for detecting lung metastases.

April 25, 2005

AuntMinnie.com Molecular Imaging Radiology Insider

By Jonathan S. Batchelor

April 24, 2005

PET/CT market on the rise

By AuntMinnie.com staff writers

The U.S. PET and PET/CT markets produced revenue of $496.6 million in 2004, according to a new report from market research firm Frost & Sullivan.

April 24, 2005

Neoprobe inks new Lymphoseek deal

By AuntMinnie.com staff writers

Gamma camera probe developer Neoprobe of Dublin, OH, has signed an agreement with the University of California, San Diego that will enable the company to expand its Lymphoseek radiopharmaceutical into applications in ultrasound and optical imaging.

April 20, 2005

Molecular Insight raises $28 million

By AuntMinnie.com staff writers

Radioisotope imaging developer Molecular Insight Pharmaceuticals of Cambridge, MA, said it has raised $28 million in Series C financing.

April 19, 2005

Philips installs first hybrid SPECT/CT units

By AuntMinnie.com staff writers

Multimodality vendor Philips Medical Systems of Andover, MA, has completed the first installations of its Precedence hybrid SPECT/CT systems.

April 18, 2005

Previous Page

Page 372 of 439

Next Page